Literature DB >> 3994325

Elimination half-life of drugs: value and limitations.

D J Greenblatt.   

Abstract

A drug's half-life of elimination from plasma or serum has long been considered a familiar and important pharmacologic property. In fact, elimination half-life has limitations, and its value has been overestimated. Elimination half-life is a dependent variable, related directly to volume of distribution and inversely to clearance. Changes in drug distribution as well as in rate of clearance can alter elimination half-life. Half-life also has limitations as a predictor of a drug's duration of pharmacologic action after single doses, which is related more to distribution than to elimination or clearance. During multiple dosage, elimination half-life does have value in predicting the rate and relative extent of drug accumulation, as well as the rate of washout after termination of treatment. Clinicians should consider volume of distribution and clearance, in addition to elimination half-life, when evaluating the pharmacokinetic properties of drugs.

Mesh:

Substances:

Year:  1985        PMID: 3994325     DOI: 10.1146/annurev.me.36.020185.002225

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  21 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Drug therapy in dental practice: general principles. Part 1 - Pharmacokinetic considerations.

Authors:  Daniel E Becker
Journal:  Anesth Prog       Date:  2006

Review 3.  Principles of pharmacotherapy: II. Pharmacokinetics.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 Jul-Aug

4.  Impact of specific Beers Criteria medications on associations between drug exposure and unplanned hospitalisation in elderly patients taking high-risk drugs: a case-time-control study in Western Australia.

Authors:  Sylvie D Price; C D'Arcy J Holman; Frank M Sanfilippo; Jon D Emery
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

5.  Tailoring Renal Clearance and Tumor Targeting of Ultrasmall Metal Nanoparticles with Particle Density.

Authors:  Shaoheng Tang; Chuanqi Peng; Jing Xu; Bujie Du; Qingxiao Wang; Rodrigo D Vinluan; Mengxiao Yu; Moon J Kim; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2016-11-24       Impact factor: 15.336

6.  Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.

Authors:  Malcolm J D'Souza; Ghada J Alabed
Journal:  Pharm Rev       Date:  2010-02-03

Review 7.  Using pharmacokinetic principles to optimize pain therapy.

Authors:  Kay Brune; Bertold Renner; Burkhard Hinz
Journal:  Nat Rev Rheumatol       Date:  2010-09-07       Impact factor: 20.543

Review 8.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Salivary Excretion of Renal-Clearable Silver Nanoparticles.

Authors:  Shaoheng Tang; Yingyu Huang; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2020-08-28       Impact factor: 15.336

10.  Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers.

Authors:  Xue-Qing Li; Roslyn Stella Thelingwani; Leif Bertilsson; Ulf Diczfalusy; Tommy B Andersson; Collen Masimirembwa
Journal:  J Pers Med       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.